Table of Content
Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Market definition
1.3. Information procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources & third-party perspectives
1.3.4. Primary research
1.4. Information analysis
1.4.1. Data analysis models
1.5. Market formulation & data visualization
1.6. Data validation & publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Global Anti-infective Agents Market Variables, Trends & Scope
3.1. Anti-infective agents Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Pipeline Analysis
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Growing geriatric population base
3.4.1.2. Growing prevalence of target diseases such as hospital acquired infections, STIs, and respiratory viruses
3.4.1.3. Increase in collaborative development efforts
3.4.2. Market Restraint Analysis
3.4.2.1. Development of multi-drug resistant organisms
3.4.2.2. High R&D cost
3.5. Anti-infective agents Market Analysis Tools
3.5.1. Industry Analysis – Porter’s
3.5.1.1. Supplier Power: Low due to large number of manufacturers
3.5.1.2. Buyer Power: Moderate due to availability of several generic products
3.5.1.3. Substitution Threat: High due to presence external substitutes
3.5.1.4. Threat from new entrant: Moderate due to high investments required in R&D and manufacturing
3.5.1.5. Competitive rivalry: High due to rigorous competition among key players
3.6. PESTEL Analysis
3.6.1. Political Landscape
3.6.2. Environmental Landscape
3.6.3. Social Landscape
3.6.4. Technology Landscape
3.6.5. Legal Landscape
3.7. Major Deals & Strategic Alliances Analysis
3.7.1. Joint Ventures
3.7.2. Mergers & Acquisitions
3.7.3. Licensing & Partnership
3.7.4. Technology Collaborations
3.7.5. Strategic Divestments
Chapter 4. Anti-infective Agents Market – Competitive Analysis
4.1. Recent developments & impact analysis, by key market participants
4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
4.3. Public Companies
4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.3.2. Company Market Share/Ranking, by region
4.3.3. Competitive Dashboard Analysis
4.3.4. Market Differentiators
4.3.5. Synergy Analysis: Major Deals & Strategic Alliances
4.4. Private Companies
4.4.1. List of key emerging companies
4.4.2. Regional network map
4.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Anti-infective Agents Market: Type Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Type market share analysis, 2018 & 2026
5.3. Type Dashboard
5.4. Global Anti-infective agents Market, by Type, 2013 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
5.5.1. Antibacterial by drug class
5.5.1.1. Antibacterial market, 2013 – 2026 (USD Billion)
5.5.1.2. Cephalosporins
5.5.1.2.1. Cephalosporins market, 2013 – 2026 (USD Billion)
5.5.1.3. Penicillin
5.5.1.3.1. Penicillin market, 2013 – 2026 (USD Billion)
5.5.1.4. Fluoroquinolones
5.5.1.4.1. Fluoroquinolones market, 2013 – 2026 (USD Billion)
5.5.1.5. Macrolides
5.5.1.5.1. Macrolides market, 2013 – 2026 (USD Billion)
5.5.1.6. Carbapenem
5.5.1.6.1. Carbapenem market, 2013 – 2026 (USD Billion)
5.5.1.7. Others
5.5.1.7.1. Others market, 2013 – 2026 (USD Billion)
5.5.2. Antibacterial by route of administration
5.5.2.1. Topical
5.5.2.1.1. Topical market, 2013 – 2026 (USD Billion)
5.5.2.2. Oral
5.5.2.2.1. Oral market, 2013 – 2026 (USD Billion)
5.5.2.3. IV
5.5.2.3.1. IV market, 2013 – 2026 (USD Billion)
5.5.2.4. Others
5.5.2.4.1. Others market, 2013 – 2026 (USD Billion)
5.5.3. Antifungal by drug class
5.5.3.1. Antifungal market, 2013 – 2026 (USD Billion)
5.5.3.2. Azoles
5.5.3.2.1. Azoles market, 2013 – 2026 (USD Billion)
5.5.3.3. Echinocandins
5.5.3.3.1. Echinocandins market, 2013 – 2026 (USD Billion)
5.5.3.4. Polyenes
5.5.3.4.1. Polyenes market, 2013 – 2026 (USD Billion)
5.5.3.5. Others
5.5.3.5.1. Others market, 2013 – 2026 (USD Billion)
5.5.4. Antifungal by route of administration
5.5.4.1. Antifungal market, 2013 – 2026 (USD Billion)
5.5.4.2. Topical
5.5.4.2.1. Topical market, 2013 – 2026 (USD Billion)
5.5.4.3. Oral
5.5.4.3.1. Oral market, 2013 – 2026 (USD Billion)
5.5.4.4. IV
5.5.4.4.1. IV market, 2013 – 2026 (USD Billion)
5.5.4.5. Others
5.5.4.5.1. Others market, 2013 – 2026 (USD Billion)
5.5.5. Antiviral by route of administration
5.5.5.1. Antiviral market, 2013 – 2026 (USD Billion)
5.5.5.2. Topical
5.5.5.2.1. Topical market, 2013 – 2026 (USD Billion)
5.5.5.3. Oral
5.5.5.3.1. Oral market, 2013 – 2026 (USD Billion)
5.5.5.4. IV
5.5.5.4.1. IV market, 2013 – 2026 (USD Billion)
5.5.5.5. Others
5.5.5.5.1. Others market, 2013 – 2026 (USD Billion)
Chapter 6. Anti-infective Agents Market: Route of Administration Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Route of administration market share analysis, 2018 & 2026
6.3. Route of Administration Dashboard
6.4. Global Anti-infective agents Market, by Route of Administration, 2013 to 2026
6.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
6.6. Topical
6.6.1. Topical market, 2013 – 2026 (USD Billion)
6.7. ‘Oral
6.7.1. Oral market, 2013 – 2026 (USD Billion)
6.8. Intravenous (IV)
6.8.1. IV market, 2013 – 2026 (USD Billion)
6.9. Others
6.9.1. Others market, 2013 – 2026 (USD Billion)
Chapter 7. Anti-infective Agents Market: Distribution Channel Estimates & Trend Analysis
7.1. Definitions & Scope
7.2. Distribution channel market share analysis, 2018 & 2026
7.3. Distribution Channel Dashboard
7.4. Global Anti-infective Agents Market, by Distribution Channel, 2013 to 2026
7.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
7.6. Hospital Pharmacy
7.6.1. Hospital Pharmacy market, 2013 – 2026 (USD Billion)
7.7. Retail Pharmacy
7.7.1. Retail Pharmacy market, 2013 – 2026 (USD Billion)
7.8. Specialty Pharmacy
7.8.1. Specialty Pharmacy market, 2013 – 2026 (USD Billion)
7.9. E-commerce
7.9.1. E-commerce market, 2013 – 2026 (USD Billion)
7.10. Others
7.10.1. Others market, 2013 – 2026 (USD Billion)
Chapter 8. Anti-infective Agents Market: Regional Estimates & Trend analysis
8.1. Regional Market Snapshot
8.2. Regional Market Share and Leading Players, 2018
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
8.5. North America
8.5.1. North America market, 2013 – 2026 (USD Billion)
8.5.2. U.S.
8.5.2.1. U.S. market, 2013 – 2026 (USD Billion)
8.5.3. Canada
8.5.3.1. Canada market, 2013 – 2026 (USD Billion)
8.6. Europe
8.6.1. Europe market, 2013 – 2026 (USD Billion)
8.6.2. U.K.
8.6.2.1. U.K. market, 2013 – 2026 (USD Billion)
8.6.3. Germany
8.6.3.1. Germany market, 2013 – 2026 (USD Billion)
8.6.4. Spain
8.6.4.1. Spain market, 2013 – 2026 (USD Billion)
8.6.5. France
8.6.5.1. France market, 2013 – 2026 (USD Billion)
8.6.6. Italy
8.6.6.1. Italy market, 2013 – 2026 (USD Billion)
8.6.7. Russia
8.6.7.1. Russia market, 2013 – 2026 (USD Billion)
8.7. Asia Pacific
8.7.1. Asia Pacific market, 2013 – 2026 (USD Billion)
8.7.2. China
8.7.2.1. China market, 2013 – 2026 (USD Billion)
8.7.3. Japan
8.7.3.1. Japan market, 2013 – 2026 (USD Billion)
8.7.4. India
8.7.4.1. India market, 2013 – 2026 (USD Billion)
8.7.5. South Korea
8.7.5.1. South Korea market, 2013 – 2026 (USD Billion)
8.7.6. Singapore
8.7.6.1. Singapore market, 2013 – 2026 (USD Billion)
8.7.7. Australia
8.7.7.1. Australia market, 2013 – 2026 (USD Billion)
8.8. Latin America
8.8.1. Latin America market, 2013 – 2026 (USD Billion)
8.8.2. Brazil
8.8.2.1. Brazil market, 2013 – 2026 (USD Billion)
8.8.3. Mexico
8.8.3.1. Mexico market, 2013 – 2026 (USD Billion)
8.8.4. Argentina
8.8.4.1. Argentina market, 2013 – 2026 (USD Billion)
8.9. Middle East Africa (MEA)
8.9.1. MEA market, 2013 – 2026 (USD Billion)
8.9.2. South Africa
8.9.2.1. South Africa market, 2013 – 2026 (USD Billion)
8.9.3. Saudi Arabia
8.9.3.1. Saudi Arabia market, 2013 – 2026 (USD Billion)
8.9.4. UAE
8.9.4.1. UAE market, 2013 – 2026 (USD Billion)
Chapter 9. Company Profiles
9.1. Strategic Framework
9.1.1. GlaxoSmithKline plc.
9.1.1.1. Company overview
9.1.1.2. Financial framework
9.1.1.3. Product benchmarking
9.1.1.4. Strategic initiatives
9.1.2. Pfizer, Inc
9.2.1.1. Company overview
9.2.1.2. Financial framework
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.1.3. Bayer AG
9.3.1.1. Company overview
9.3.1.2. Financial framework
9.3.1.3. Product benchmarking
9.3.1.4. Strategic initiatives
9.1.4. Sanofi
9.4.1.1. Company overview
9.4.1.2. Financial framework
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.1.5. Merck & Co., Inc.
9.5.1.1. Company overview
9.5.1.2. Financial framework
9.5.1.3. Product benchmarking
9.5.1.4. Strategic initiatives
9.1.6. Bristol-Myers Squibb Company
9.6.1.1. Company overview
9.6.1.2. Financial framework
9.6.1.3. Product benchmarking
9.6.1.4. Strategic initiatives
9.1.7. Abbott
9.7.1.1. Company overview
9.7.1.2. Financial framework
9.7.1.3. Product benchmarking
9.7.1.4. Strategic initiatives
9.1.8. Novartis AG
9.8.1.1. Company overview
9.8.1.2. Financial framework
9.8.1.3. Product benchmarking
9.8.1.4. Strategic initiatives
9.1.9. Johnson & Johnson Services, Inc
9.9.1.1. Company overview
9.9.1.2. Financial framework
9.9.1.3. Product benchmarking
9.9.1.4. Strategic initiatives
9.1.10. Astellas Pharma Inc
9.10.1.1. Company overview
9.10.1.2. Financial framework
9.10.1.3. Product benchmarking
9.10.1.4. Strategic initiatives
9.1.11. Gilead Sciences, Inc.
9.11.1.1. Company overview
9.11.1.2. Financial framework
9.11.1.3. Product benchmarking
9.11.1.4. Strategic initiatives
【掲載企業】
GlaxoSmithKline plc., Pfizer, Inc, Bayer AG, Sanofi, Merck & Co., Inc., Bristol-Myers Squibb Company, Abbott, Novartis AG, Johnson & Johnson Services, Inc, Astellas Pharma Inc, Gilead Sciences, Inc.
【免責事項】
https://www.globalresearch.jp/disclaimer